Search results for:
Ondine joins CAN Health Network
Ondine Biomedical Joins CAN Health Network to Advance its Innovation in Infection Prevention Across Canada Membership provides strategic support, insights and connections as Ondine works to scale its infection prevention technology. Ondine Biomedical Inc. (LON: OBI) is pleased to announce its membership with the CAN Health Network — a [...]
Ondine commencing US Phase 3 clinical trial
Ondine announced today the imminent start of the LANTERN Phase 3 clinical trial of its novel nasal photodisinfection technology, branded as Steriwave® outside the US. The U.S. Food and Drug Administration (FDA) has raised no objections to starting the study during its statutory 30-day review period of the Company's [...]
Ondine CMO interviewed in European Biopharmaceutical Review
Ondine Biomedical's Chief Medical Officer, Simon Sinclair, has been interviewed for the Summer edition of European Biopharmaceutical Review about the risks of AMR and rising rates of hospital infections. Read the full interview here: Antimicrobial resistance and healthcare-associated infections: the current landscape and the future.
Burnaby Hospital deploys Steriwave
Burnaby Hospital in British Columbia has deployed Steriwave nasal photodisinfection to help prevent surgical site infections and optimize patient outcomes. Vancouver, British Columbia, Canada - September 29, 2023 Burnaby Hospital, a large community hospital in British Columbia, has initiated use of Ondine Biomedical’s (OBI:LON) [...]
BBC News features first NHS pilot of Steriwave
BBC Look North evening news feature: A pioneering laser treatment which could cut the risk of drug-resistant infections after operations is being trialled for the first time in the UK. A six-month NHS pilot will see 500 patients given Ondine Biomedical's Steriwave® nasal photodisinfection at Pontefract Hospital in [...]
Bloomberg articles: Killing Bugs in the Nose
Bloomberg publishes articles on Steriwave™ nasal photodisinfection International - February 24, 2023 Today, Bloomberg published an article in both its newsletter and in Businessweek about Ondine Biomedical’s Steriwave™ nasal photodisinfection: Newsletter: Killing Bugs in the Nose Businessweek: Germ-Zapping Lasers Help Cut Down on Infections [...]
First patients treated in US Phase 2 trial
Ondine Biomedical treats first patients in nasal photodisinfection US Phase 2 trial for the prevention of post-operative infections Vancouver, British Columbia, Canada - February 7, 2022 Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare [...]
Photodisinfection could be game-changer in fight against resistance
Photodisinfection technology could be a game-changer in fight against antimicrobial resistance Vancouver, British Columbia, Canada - January, 2022 Ondine Biomedical’s photodisinfection technology is one of the only new technologies available to economically combat drug-resistant infections. An analysis published in the Lancet found that 1.27 [...]
Seasoned health executive joins Ondine to lead sales and marketing
Ondine Biomedical appoints Charles Young to lead sales and marketing activity in North America Vancouver, British Columbia, Canada – January 5, 2022 Ondine Biomedical Inc. (LON:OBI) has appointed Charles Young as its VP Sales & Marketing, North America to lead the commercialization of its antimicrobial photodisinfection-based [...]
Ondine Biomedical appoints new Board of Directors
Ondine Biomedical appoints new Board of Directors Vancouver, British Columbia, Canada - December 8, 2021 Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market. Key appointments include [...]
For Media Information
Simon Vane Percy
Amanda Bernard
